Moventig is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). For definition of inadequate response to laxative(s), see section 5.1.
Further analysis of the Phase III KODIAC-04, KODIAC-05 and KODIAC-08 studies showed that Movantik (naloxegol), from AstraZeneca, had a similar...
AstraZeneca has filed a new drug submission with the FDA for Naloxegol (naxolol), for the treatment of Opioid induced Constipation....
AstraZeneca has announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for Naloxegol, an investigational...
Two Phase III trials and one safety extension trial of Naloxegol (naxolol), from AstraZeneca, in patients with non-cancer related pain...
The National Institute for Health and Care Excellence (NICE) in new final guidelines has recommended Moventig (naloxegol) from AstraZeneca as...
AstraZeneca announced a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik (naloxegol) in the USA. Under the terms of the...
New results from KODIAC-08, an open-label, randomised, 52-week, long-term safety trial of Naloxegol (naxolol), from AstraZeneca, in patients with non-cancer...
To update and expand the 2013 Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the ICU.